Evidence Level:Sensitive: A2 - Guideline
New
Excerpt:Colon Cancer...SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE - CHEMOTHERAPY REGIMENS...FOLFIRI + panitumumab (KRAS/NRAS/BRAF WT and left-sided tumors only)...Irinotecan + panitumumab (KRAS/NRAS/BRAF WT and left-sided tumors only)...FOLFOX + panitumumab (KRAS/NRAS/BRAF WT and left-sided tumors only)...FOLFIRINOX or mFOLFIRINOX + panitumumab (KRAS/NRAS/BRAF WT and left-sided tumors only)
Secondary therapy:irinotecan; FOLFIRINOX; FOLFOX; FOLFIRI
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Excerpt:...- Wild-type KRAS expressing mCRC from the primary tumor or metastasis....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases
More C2 evidence
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
Excerpt:...- Subjects with wild-type KRAS tumor status confirmed by an Amgen approved central laboratory assessment or an experienced local laboratory assessment of archival tumor tissue (preferably from the primary tumor);...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Excerpt:...Tumor tissue must reveal wild-type KRAS expression (i.e....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy
Excerpt:...- Subjects with wild-type KRAS tumor status confirmed by central laboratory assessment of paraffin-embedded tumor tissue from the primary tumor or metastasis....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer
Excerpt:...To estimate the PFS by DP immunohistochemistry (IHC) expression in patients with wild-type KRAS mCRC treated with panitumumab and mFOLFOX6. ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
FOLFOXIRI plus Panitumumab or FOLFOX plus Panitumumab in the treatment of metastatic colorectal cancer. folfoxiri più panitumumab contro folfox più panitumumab nel carcinoma del colonretto metastatico.
Excerpt:...Histologically proven diagnosis of colorectal cancer.Initially unresectable metastatic colorectal cancer not previously treated with chemotherapy for metastatic disease.At least one measurable lesion according to RECIST1.1Availability of a tissue tumour sample (primary tumour and/or metastatic sites)Previous adjuvant chemotherapy allowed only if with fluoropyrimidine monotherapy and more than 6 months elapsed between the end of adjuvant and first relapse.RAS (codons 12, 13, 59, 61, 117 and 146 of KRAS and NRAS genes) and BRAF (V600E mutation) wild type status of primary colorectal cancer or related metastasis (local or central laboratory assessment). ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Excerpt:...- Wild-type KRAS tumor status confirmed by an Amgen approved central laboratory or an experienced laboratory (local laboratory) per local regulatory guidelines using a validated test method...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer
Excerpt:...- Wild-type KRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) and wild-type NRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) tumor status....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Excerpt:...- Wild-type KRAS tumor status...
